A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

An artificial intelligence system slightly outperformed radiologists using PI-RADS at detecting clinically significant prostate cancer. A trained artificial intelligence (AI) system discriminated ...

AI-assisted imaging improved prostate cancer diagnosis and biopsy decision-making in new research presented at EAU 2026.

Researchers have found a link between low testosterone levels and aggressive tumors, which could change how prostate cancer ...

But does it cost too much?

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...

A combined PSMA-PET/MRI scanner better detected clinically significant prostate cancer in men on active surveillance. The addition of piflufolastat F18 (18 F-DCFPyL) prostate-specific membrane antigen ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager". This type of immunotherapy ignites our own ...